Sandoz-adalimumab (SDZ-ADL; Hyrimoz®, GP2017) is an adalimumab (ADL) biosimilar approved for the treatment of immune-mediated inflammatory diseases, including psoriasis, inflammatory bowel disease, and several inflammatory rheumatic diseases

This literature review covers published clinical and real-world evidence on the efficacy and safety of SDZ-ADL across approved indications in detail

In clinical trials, the efficacy, safety, and immunogenicity of SDZ-ADL have been shown to match those observed for reference adalimumab (ref-ADL) and are not impacted by single or multiple drug switches

These clinical observations are substantiated by evidence from real-world studies, confirming the effectiveness and safety of SDZ-ADL in both biologic-naïve patients and those switching from ref-ADL or other ADL biosimilars

The findings of this literature review support that SDZ-ADL is as effective and safe as ref-ADL in both biologic-naïve and biologic-experienced patients and should enhance confidence in SDZ-ADL among clinicians and patients